Persevere Therapeutics
PrivateLast Round
Seed
Feb 11, 2026
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Persevere Therapeutics operates in Healthcare & Life Sciences and is based in Chesterbrook, Pennsylvania. It was founded in 2025.
Persevere Therapeutics is an oncology biotechnology company that develops misetionamide, a novel antineoplastic therapeutic for patients with difficult-to-treat cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Persevere Therapeutics Comparables
Compare Persevere Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Vortex Therapeutics, Inc. | 82% | |
| Peptomyc | 74% | |
| Jazz Pharmaceuticals | 59% |
For institutional investors. Book with your work email.
Persevere Therapeutics Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 11, 2026
$1.6M raised in Seed round.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresSep 4, 2026
Persevere Therapeutics, Inc. appoints oncology executive James Barlow to its board in Pennsylvania as it prepares to begin a Phase 2a trial of misetionamide and pursues funding for a separate pancreatic cancer study.
- hiresAug 31, 2026
Persevere Therapeutics, Inc. appoints biotech executive James (Jim) Barlow to its Board of Directors in Pennsylvania on Aug 31st '26, as the clinical-stage oncology company advances its misetionamide program.
- recognized_asAug 31, 2026
Persevere Therapeutics, Inc. is recognized by the Cancer Prevention and Research Institute of Texas (CPRIT) as a 2026 CPRIT Finalist to fund a randomized Phase 2 combination trial in pancreatic cancer.
For institutional investors. Book with your work email.
Persevere Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Persevere Therapeutics's valuation, stock price, and market status.
Is Persevere Therapeutics a public or private company?
Persevere Therapeutics is a private company.
What is the current stock price of Persevere Therapeutics?
Persevere Therapeutics is a private company, so its shares have no public market price. Caplight tracks Persevere Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Persevere Therapeutics worth (valuation)?
Valuation information for Persevere Therapeutics is not publicly available.
Can I buy Persevere Therapeutics stock?
Persevere Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Persevere Therapeutics's last funding round?
Persevere Therapeutics's most recent funding round was Seed on February 11, 2026.
Who are the main investors in Persevere Therapeutics?
Investor information for Persevere Therapeutics is not publicly disclosed.
Will Persevere Therapeutics IPO soon?
No public IPO plans have been announced for Persevere Therapeutics.
How can I track Persevere Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Persevere Therapeutics's shares on secondary markets.